David Main, CEO and president of Aquinox Pharmaceuticals Inc., introduces the company he founded in 2006, which now is in the late stages of development of a drug targeting the SHIP1 enzyme, with a focus on treating interstitial cystitis/bladder pain syndrome. Other applications may include blood cancers and chronic prostatitis/chronic pelvic pain syndrome. Aquinox Pharmaceuticals has the ambition to become a global biotechnology player. How was Aquinox Pharmaceuticals founded and what have been the beginnings of the company?
"Health Canada has done a good job of harmonizing the approval process based upon safety and efficacy, but there are numerous agencies, both federal and provincial, involved in pricing and reimbursement."